Advanced in Scleroderma

Lingyun Y. Sun

321 Zhongshan Road, 
Nanjing, CN 
Advanced in Scleroderma
321 Zhongshan Road, 
Nanjing, CN 
OverviewLocationsClinical Research

Overview

Lingyun Sun practices in Nanjing, China. Sun is rated as an Advanced expert by MediFind in the treatment of Scleroderma. Their top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Sjogren Syndrome, Bone Marrow Transplant, and Liver Transplant.

Their clinical research consists of co-authoring 387 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 21 articles in the study of Scleroderma.

Locations

321 Zhongshan Road, Nanjing, 210008, China
Other Locations
No. 321 Zhongshan Road, Nanjing, 210008, China
NO.321 Zhongshan Road, Nanjing, China
140 Hanzhong Road, Nanjing, 210029, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drug: Ixekizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 2 Less Clinical Trials

387 Total Publications

Patients' Expectations and Barriers Toward Reishi Mushroom Use in Cancer Care: A Cross-Sectional Survey.
Patients' Expectations and Barriers Toward Reishi Mushroom Use in Cancer Care: A Cross-Sectional Survey.
Journal: Integrative cancer therapies
Published: September 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sun's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 53 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile